Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3‐internal tandem duplication positive acute myeloid Leukaemia
- 3 November 2011
- journal article
- other
- Published by Wiley in British Journal of Haematology
- Vol. 157 (1), 131-132
- https://doi.org/10.1111/j.1365-2141.2011.08910.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapseBlood, 2011
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivoBlood, 2011
- Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II TrialBlood, 2010
- Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutationsAnnals of Hematology, 2010
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia.Blood, 2009
- Clinical Efficacy of Sorafenib in Patients with Acute Myeloid Leukemia (AML) and Activating FLT3-Mutations.Blood, 2009
- Compassionate use of sorafenib in FLT3-ITD–positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantationBlood, 2009
- Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimensLeukemia & Lymphoma, 2008
- In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effectsBlood, 2004